Investor Presentation

Dermatomyositis Overview Rare and serious autoimmune condition related to SSc and characterized by skin and muscle inflammation ~80,000 people with DM in US, EU and Japan¹ 30% mortality in 5 years² 26 X 1: Health Advances, LLC; Lenabasum Commercial Market Assessments; 2: Schiopu et al, 2012 Zero DM-specific drugs approved Lenabasum ~$1B - $2B annual potential market opportunity for lenabasum¹

View entire presentation